Subscribe to RSS
IL-10 Polymorphism and Breast Cancer Risk in Georgian Women: A Case–Control StudyFunding This study was supported by the Shota Rustaveli National Science Foundation of Georgia (grant number #FR-21-17599).
Background Interleukin-10 (IL-10) is a cytokine with a vast variety of functions, but its role in cancer development and progression is not yet clear. It is involved in two of the hallmarks of cancer: vascularization and immune modulation. IL-10 inhibits angiogenesis and hence is antitumorigenic. But it also can suppress the immune system and be tumorigenic.
Objective Evaluating the role of IL-10 (-1082 A/G) gene promoter single-nucleotide polymorphism (SNP) in breast cancer susceptibility and progression in Georgian women.
Methods A case–control study was performed on a total of 128 women, with 64 of them being histologically confirmed to have breast cancer and 64 healthy controls. SNP genotyping was performed with TaqMan assay with real-time polymerase chain reaction. And pathology report, containing proliferative activity and breast cancer hormonal status, was obtained after surgery of the case individuals. Statistical analysis was done to investigate the significance of data obtained from genotyping and histology reports.
Results Statistical analysis revealed that the difference in frequency of genotypes was not statistically significant between cases and controls (chi-square = 0.5812, p = 0.7478). The comparison of proliferative activity of cases with AA genotypes and AG/GG genotypes showed no statistical difference (t = 0.2575, p = 0.7980). Although when put into a plot (box and whiskers), patients with AG/GG genotype have outliers with very high proliferative activity.
Conclusion This study shows that -1082 A/G SNP in the promoter region of the IL-10 gene is not associated with breast cancer risk in Georgian women.
Keywordsinterleukin-10 - single-nucleotide polymorphism - breast cancer - RT-PCR - proliferative activity
The study is approved by the Ethics Committee of Tbilisi State Medical University, Georgia under approval number #44/3 with the following members: 1. Givi Javashvili, Chair of the Ethics Committee; 2. Guram Kiknadze; 3. Tamar Kurtanidze; 4. Davit Gelovani; 5. Irma Manjavidze; 6. Ramaz Shengelia; 7. Temur Silagadze; 8. Zaza Chafichadze; 9. Zaza Berishvili; 10. Magda Bethaneli; 11. Akaki Barkalaya; 12. Gocha Shatirishvili.
Consent to Participate
Signed informed consent was collected from every study participant.
Availability of Data and Materials
In case you want to access our PCR raw data, you can contact the first author by email at: email@example.com.
Article published online:
10 July 2023
© 2023. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
- 1 Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin 2019; 69 (01) 7-34
- 2 Oldenburg RA, Meijers-Heijboer H, Cornelisse CJ, Devilee P. Genetic susceptibility for breast cancer: how many more genes to be found?. Crit Rev Oncol Hematol 2007; 63 (02) 125-149
- 3 Janikashvili N, Bonnotte B, Katsanis E, Larmonier N. The dendritic cell-regulatory T lymphocyte crosstalk contributes to tumor-induced tolerance. Clin Dev Immunol 2011; 2011: 430394
- 4 Syrjänen S, Naud P, Sarian L. et al. Immunosuppressive cytokine interleukin-10 (IL-10) is up-regulated in high-grade CIN but not associated with high-risk human papillomavirus (HPV) at baseline, outcomes of HR-HPV infections or incident CIN in the LAMS cohort. Virchows Arch 2009; 455 (06) 505-515
- 5 Bhairavabhotla RK, Verm V, Tongaonkar H, Shastri S, Dinshaw K, Chiplunkar S. Role of IL-10 in immune suppression in cervical cancer. Indian J Biochem Biophys 2007; 44 (05) 350-356
- 6 Kundu N, Fulton AM. Interleukin-10 inhibits tumor metastasis, downregulates MHC class I, and enhances NK lysis. Cell Immunol 1997; 180 (01) 55-61
- 7 Huang S, Xie K, Bucana CD, Ullrich SE, Bar-Eli M. Interleukin 10 suppresses tumor growth and metastasis of human melanoma cells: potential inhibition of angiogenesis. Clin Cancer Res 1996; 2 (12) 1969-1979
- 8 An L, Dou X, Wang M, Luo W, Ma Q, Liu X. Involvement of TNF-alpha and IL-10 in breast cancer and patient survival. Trop J Pharm Res 2020; 19 (10) 2033-2039
- 9 AlSuhaibani ES, Kizilbash NA, Malik S, Dasti JI, Al Beladi F, El-Morshedi N. Polymorphisms in promoter regions of IL-6 and IL-10 genes in breast cancer: a case-control study. Genet Mol Res 2016;15(01):
- 10 Kang X, Kim HJ, Ramirez M, Salameh S, Ma X. The septic shock-associated IL-10 -1082 A > G polymorphism mediates allele-specific transcription via poly(ADP-Ribose) polymerase 1 in macrophages engulfing apoptotic cells. J Immunol 2010; 184 (07) 3718-3724
- 11 Howell WM, Rose-Zerilli MJ. Interleukin-10 polymorphisms, cancer susceptibility and prognosis. Fam Cancer 2006; 5 (02) 143-149
- 12 Vinod C, Jyothy A, Vijay Kumar M, Raman RR, Nallari P, Venkateshwari A. A common SNP of IL-10 (-1082A/G) is associated with increased risk of premenopausal breast cancer in South Indian women. Iran J Cancer Prev 2015; 8 (04) e3434
- 13 Giordani L, Bruzzi P, Lasalandra C. et al. Association of breast cancer and polymorphisms of interleukin-10 and tumor necrosis factor-α genes. Clin Chem 2003; 49 (10) 1664-1667
- 14 Kong F, Liu J, Liu Y, Song B, Wang H, Liu W. Association of interleukin-10 gene polymorphisms with breast cancer in a Chinese population. J Exp Clin Cancer Res 2010; 29 (01) 72
- 15 Abdolrahim-Zadeh H, Hakkakian N, Asadollahi R. et al. Interleukin-10 promoter polymorphisms and breast cancer risk in Iranian women. Iran J Immunol 2005; 2 (03) 158-165
- 16 Molino A, Micciolo R, Turazza M. et al. Ki-67 immunostaining in 322 primary breast cancers: associations with clinical and pathological variables and prognosis. Int J Cancer 1997; 74 (04) 433-437
- 17 Nishimura R, Osako T, Okumura Y, Hayashi M, Toyozumi Y, Arima N. Ki-67 as a prognostic marker according to breast cancer subtype and a predictor of recurrence time in primary breast cancer. Exp Ther Med 2010; 1 (05) 747-754